HASAN ERHUN KASIRGA, İpek AKİL, Şenol COŞKUN, Ali Aykan ÖZGÜVEN, Zehra KARAKOÇ

Akut hepatit A virus infeksiyonuna bağlı kolestazda ursodeoksikolik asit tedavisi

Ursodeoksikolik asit hidrofilik ve non-toksik bir safra asidi olup kronik kolestatik hepatitin ternel tedavisidir. Daha önceden yayınlanmış çalışmalarda akut viral hepatitin erişkinlerdeki seyri üzerinde bazı yararlı etkileri olduğu gösterilmiştir.Bu olgu bildirisinde, hepatit A virus infeksiyonuna bağlı kolestazı olan 5 ve 12 yaşlarında iki çocuk sunuldu. Hastalarımızda bir aylık ursodeoksikolik asit tedavisinden sonra klinik ve laboratuvar belirtileri düzeldi.Ursodeoksikolik asitin akut hepatit A virus infeksiyonuna bağlı kolestazın seyri üzerinde yararlı etkisi olduğu düşünüldü.

Anahtar Kelimeler:

Ursodeoksikolik asit, Hepatit A, Kolestaz

Ursodeoxycholic acid treatment in acute hepatitis A virus infection-related cholestasis

Ursodeoxycholic acid is a hydrophilic and non-toxic bile acid which is recognized as a main treatment for chronic cholestatic hepatitis. In previously published studies ursodeoxycholic acid showed some beneficial effects on the course of acute viral hepatitis in adults. In this case report, two children aged 5 and 12 years old with hepatitis A virus infection-related cholestasis were presented. The clinical and laboratory manifestations were improved after one-month-ursodeoxycholic acid therapy in our patients. We conclude that ursodeoxycholic acid has a beneficial effect on the course of the acute hepatitis A virus infection-related cholestasis.

Keywords:

Ursodeoxycholic Acid, Hepatitis A, Cholestasis,

PDF

___

1. Scholmerich J, Becher MS, Schmidt K, Schubert R, Kremer B, Feldhaus S, Gerok W. Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties-studies on isolated hepatocytes and lipid membrane vesicles. Hepatology 1984; 4(4): 661-666. 2. Trauner M, Graziadei IW. Review article: Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmocol Ther 1999;13:979-995. 3. Kumar D, Tandon RK. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol 2001;16(1):3-14. 4. Paumgartner G, Beuers U. Ursodeoxycholic Acid in Cholestatic Liver Disease: Mechanisms of Action and Therapeutic Use Revisited. Hepatology 2002; 36(3): 525-531. 5. Fabris P, Tositti G, Mazella G. Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study. Aliment Pharmocol Ther 1999;13:1187-1193. 6. Galsky J, Bansky G, Holubova T, Konig J. Effect of Ursodeoxycholic acid in acut viral hepatitis. J Clin Gastroenterol 1999;28(3):249-253. 7. Koçak N, Saltuk N. The effect of UDCA in children with prolonged hepatitis A virus infection that may be a trigger factor for autoimmune hepatitis. Am J Gastroenterol 2001;96:610-611. 8. Kadayıfçı A, Sava MC, Arslan S, Güllü . Ursodeoxycholic Acid in the Management of Prolonged Cholestasis of Acute Hepatitis B. J Clinical Gastroenterol 1997; 24(2):125-126. 9. Ciocca M. Clinical course and consequences of hepatitis A infection. Vaccine 2000;18:71-74. 10. Cuthbert JA. Hepatitis A: Old and new. Clin Microbiol Rev 2001;14:38-58. 11. Koff RS. Hepatitis A. Lancet 1998;341:1643-1649.